Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
Mayo Clinic
Roswell Park Cancer Institute
Hoffmann-La Roche
ViroMissile, Inc.
Arcus Biosciences, Inc.
Bristol-Myers Squibb
Duke University
Tizona Therapeutics, Inc
A2 Biotherapeutics Inc.
Canadian Cancer Trials Group
Wake Forest University Health Sciences
Poseida Therapeutics, Inc.
MacroGenics
Alliance for Clinical Trials in Oncology
City of Hope Medical Center
National Institutes of Health Clinical Center (CC)
NRG Oncology
Ocellaris Pharma, Inc.
Novartis
Mayo Clinic
GlaxoSmithKline
Memorial Sloan Kettering Cancer Center
NeoTX Therapeutics Ltd.
OncoHost Ltd.
Bolt Biotherapeutics, Inc.
Nanobiotix
ITM Oncologics GmbH
Actym Therapeutics, Inc.
Janux Therapeutics
Sichuan Baili Pharmaceutical Co., Ltd.
Scancell Ltd
Travera Inc
A2 Biotherapeutics Inc.
Exelixis
Incyte Corporation
Jonsson Comprehensive Cancer Center
Xencor, Inc.
NuCana plc
A2 Biotherapeutics Inc.
NextPoint Therapeutics, Inc.
NRG Oncology
UNICANCER
Merus B.V.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Stanford University
Stanford University
Sotio Biotech Inc.